 Shares of RNA interference concern Arrowhead Pharmaceuticals are down over 50 since making an all-time high in June 2021. The companys approach has been validated by its four licensing deals, rival Alnylams commercial success, and Novo Nordisks buyout of RNAi concern Dicerna in 2021. 